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Abstract Retinoic acid (RA) a¡ects many cell types by either
promoting their survival or inducing their di¡erentiation. Dehy-
droepiandrosterone (DHEA), a precursor for both androgenic
and estrogenic steroids and abundantly produced by brain, is
known as an inhibitor of cell proliferation. Di¡erentiation of a
human neuroblastoma cell line (SK-N-BE) was evaluated mea-
suring growth rate, motility, neurite extension and GAP-43 ex-
pression. We report that DHEA enhances the di¡erentiating
e¡ect of RA on neuroblastoma cells via a signalling that is
not RA receptor-mediated. Instead, we show a di¡erential ex-
pression of matrix metalloproteinases: RA enhances the activity
of MMP-2, whereas MMP-9 expression is up-regulated by
DHEA. The concerted modulation of these proteinases may
support the neurite outgrowth observed after co-treatment with
the two drugs.
2 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Retinoic acid (RA) and related vitamin A derivatives exert
profound e¡ects on cell proliferation, di¡erentiation, and
morphogenesis [1^2]. They are considered important pro-
moters of embryonic development and tissue di¡erentiation
maintenance [3]. Retinoids act via two families of nuclear
receptors: RA receptors (RARs) and retinoid X receptors
(RXRs), members of the steroid/thyroid/retinoid superfamily
of inducible transcription factors. Both active as homo- or
hetero-dimers, the three subtypes of RARs and RXRs, K, L
and Q, di¡er in temporal and spatial distribution and in ligand
a⁄nity [4,5]. RAR L plays a critical role in mediating the
growth-inhibitory e¡ect of retinoids in many di¡erent types
of cancer cells [6,7]. A similar role is exerted by RAR K,
whose expression is elicited by estrogens in breast cancer cells
[8]. RXRs can heterodimerize also with other nuclear factors
of the steroid family, therefore representing a critical check-
point of several intracellular crosstalks [9,10].
With the aim of investigating patterns of co-operation lead-
ing to neuronal cell di¡erentiation, we have focused our at-
tention on steroids whose activity can promote di¡erentiation.
Dehydroepiandrosterone (DHEA) and its sulfate ester
(DHEAS) are the precursors of both estrogenic and andro-
genic steroids. DHEA concentrations are particularly high in
the brain, and DHEA and related steroids can be synthesized
de novo in brain glial cells [11]. Therefore, they are considered
‘neurosteroids’ and as such it is believed they exert a neuro-
protective function, although the molecular mechanisms are
not clear [12^14]. Furthermore, it is unknown if all the e¡ects
attributed to DHEA are mediated by DHEA or by its metab-
olites. No nuclear or any other type of receptor system has
been described for DHEA or DHEAS. However, recent stud-
ies have pointed out alternative mechanisms by which these
steroids exert their biological action on nervous system via
non-classic steroid hormone receptors [15].
Neurite elongation, the hallmark of neuronal di¡erentia-
tion, results from cytoskeleton reorganization and extracellu-
lar matrix (ECM) invasion. Matrix metalloproteinases (MMP)
of several kinds are crucial components of the enzyme cascade
responsible for ECM remodelling in cell invasion processes,
and among them MMPs of 72 kDa (MMP-2 or gelatinase A)
and 92 kDa (MMP-9 or gelatinase B) are the most character-
ized proteinases [16,17]. The di¡erentiating e¡ects of RA also
include the control of MMP genes: RA promotes MMP-2
expression levels as well as MMP-9 activity [18,19]. Moreover,
DHEAS is able to stimulate the production of gelatinolytic
metalloproteinases [20].
Neuroblastoma cell lines are commonly used as in vitro
models to study the di¡erentiation and development of neuro-
nal cells. In order to investigate a possible crosstalk of neuro-
steroids and retinoids in promoting cell di¡erentiation, we
used a human neuroblastoma SK-N-BE cell line able to di¡er-
entiate to a neuronal-like phenotype by producing neurite
outgrowth in response to RA [18,21]. DHEA, on the other
hand, exerts an anti-proliferative e¡ect on other human neu-
roblastoma cell lines [22,23].
Evidences provided by this study point out a synergistic
e¡ect of RA and DHEA in promoting neuroblastoma cell
di¡erentiation, which has been analyzed in terms of growth
rate, cellular motility, neurite elongation and expression of a
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neuronal di¡erentiation marker, the growth-associated protein
43 (GAP-43). Some aspects of the molecular mechanisms re-
sponsible for such a synergy have been investigated.
2. Materials and methods
2.1. Cell culture and proliferation assay
SK-N-BE cells were cultured in DMEM (Gibco, Paisley, UK) with-
out phenol red supplemented with 10% fetal bovine serum, 100 000 U/l
penicillin, 100 mg/l streptomycin and 2 mM L-glutamine at 37‡C in a
humidi¢ed 5% CO2 atmosphere. Cells were treated for the reported
time with 10 WM all-trans RA (Sigma Chemical, St. Louis, MO), 100
WM DHEA (Fluka, Buchs, Switzerland), RA and DHEA together or
solvent alone (ethanol) as control, with periodical replacement of
medium. For proliferation studies, cells were seeded in 24-well plastic
tissue culture dishes. After nine days of incubation viable cells were
stained with 0.1% crystal violet in 20% methanol for 20 min, washed
o¡ with water and then solubilized with 10% acetic acid. Optical ab-
sorbance was measured at 590 nm using a microplate reader (EL-340,
Bio-Tek Instruments, Winooski, VT, USA).
2.2. Movement and neurite growth
For time lapse experiments, cells were seeded in T-25 £asks. After 3
days of treatment the medium was replaced with a HEPES-bu¡ered
medium (SGG medium: 114 mM NaCl, 26.1 mM NaHCO3, 5.3 mM
KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM HEPES, 1 mM glycine, 30
mM glucose, 0.5 mM sodium pyruvate, 0.001% phenol red). Cell
movement was studied over a 12-hour period under a Nikon Diaphot
inverted microscope with a 10U phase-contrast objective in an at-
tached, hermetically sealed Plexiglas Nikon NP-2 incubator at 37‡C.
Cell migration was recorded using a JVC-1CCD video camera. Image
analysis was performed with a MicroImage analysis system (Cast
Imaging, Venice, Italy) and an IBM-compatible system equipped
with a video card (Targa 2000, Truevision, Santa Clara, CA, USA).
The sequence of images was analyzed in order to reconstruct the
movements, which were then quanti¢ed multiplying the length of
the path covered by each cell by the distance between the initial
and ¢nal positions. The ¢rst and last frames were compared in order
to calculate neurite growth after 12 h of treatment.
2.3. Immuno£uorescence analysis
Cells were grown on poly-lysine coated glass coverslips and ana-
lyzed as previously described [24] with some modi¢cations. Brie£y, at
the end of treatments cells were ¢xed in 3% paraformaldehyde, 4%
sucrose in PBS at room temperature for 20 min and washed with 10
mM glycine in PBS. After permeabilization with 0.5% NP-40 in PBS
for 5 min, and blocking for 20 min in 1.5% normal goat serum in
PBS, cells were treated overnight with a polyclonal antibody against
GAP-43 (dil. 1:400; Chemicon International, Temecula, CA, USA).
Afterwards cells were washed, incubated with a biotinylated second-
ary antibody and with £uorescein-avidin D and mounted. Cells were
observed under an Olympus £uorescence microscope, and pictures
taken with an Olympus DP10 digital photomicrography system.
2.4. Western blot
Immunoblotting of proteins was performed as described previously
[25] with the following modi¢cations. Treated cells were harvested by
lysis in a sample bu¡er (100 mM Tris^HCl, pH 6.8, 0.01% bromo-
phenol blue, 2% SDS, 15% glycerol, 10 mM DTT). Equal amounts of
proteins (30 Wg) were loaded, together with pre-stained full-range
molecular weight standards (Amersham, Buckinghamshire, UK) and
resolved on 10% SDS^PAGE. Proteins were transferred onto PVD
membranes, which were blocked, immunostained with the indicated
primary antibodies (all antibodies from Santa Cruz Biotechnology,
Santa Cruz, CA, USA) for 1 h at room temperature, and then with
secondary antibody conjugated to horseradish peroxidase. Proteins of
interest were detected by ECL method (Perkin Elmer Life Science,
Boston, MA, USA).
2.5. Gelatinase zymography
In order to assess the expression of metalloproteinases, gelatin zy-
Fig. 1. SK-N-BE cell movements recorded at the third day of treatment with RA and DHEA alone or in combination. Cellular movements
were tracked for 12 h and A shows the reconstruction of such movements in a set of experiments representative of a total of three. B: Quanti-
¢cation plotted as a graph, as indicated in Section 2. Values are expressed in comparison to the control and represent the meanUS.E.M. for
n=3. *P6 0.02 vs. control; **P6 0.005 vs. control. Bar= 100 Wm.
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mogram analysis was performed according to the method of Heussen
et al. [26] with some modi¢cations. After 8 days of treatment cells
were starved overnight with fresh medium supplemented with 1%
FBS, supernatants were collected and cells were lysed in lysis bu¡er
(1% Triton X-100, 50 mM Tris, 300 mM NaCl, pH 7.5). Equal
amounts of cell lysate proteins (30 Wg) and volumes of conditioned
medium proportional to cell numbers (5 Wl/106 cells) were run under
non-reducing conditions in 8% SDS^PAGE containing 0.1% gelatin.
After electrophoresis, the gels were washed twice for 1 h each in 2.5%
Triton X-100 to remove SDS and then incubated at 37‡C in collage-
nase bu¡er (50 mM Tris^HCl, 200 mM NaCl, 10 mM CaCl2, pH 7.5)
for 16 h or 5 days. After incubation, the gels were stained with Coo-
massie brilliant blue R-250 and destained in water, allowing the de-
tection of clear areas of digestion in a blue-stained gelatin back-
ground.
2.6. Statistical analysis
All data in text and ¢gures are given as meansUS.E.M. Statistical
analysis was carried out using the Student’s t-test for unpaired data.
3. Results
3.1. RA and DHEA inhibit cellular proliferation
Both RA and DHEA are known as growth arrest media-
tors; we have therefore veri¢ed their e¡ect on SK-N-BE cells
proliferation. Growth rate of untreated cells or cells treated
for 9 days with all-trans RA (10 WM), with DHEA (100 WM)
and with a combination of all-trans RA and DHEA was eval-
uated by crystal violet staining. Our data con¢rm the anti-
proliferative e¡ect of RA and DHEA on neuroblastoma cells,
and indicate that growth inhibition is even more evident when
the two agents are used in combination (data not shown).
3.2. E¡ect of RA and DHEA on cellular motility
By time lapse experiments, spontaneous movements of neu-
roblastoma cells were recorded and evaluated by a software
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Fig. 2. Neurite growth promoted by RA and DHEA. A: Pictures show a ¢eld of control or di¡erentiating cells observed for 12 h as in Fig. 1,
and are an example of a frame taken at time zero (T=0) and after 12 h (T=12), out of three experiments. Using the same frames, initial
length of neurites at T=0 was measured and plotted on a graph shown in B, whereas in C neurite growth during the 12 h was calculated as
ratio between total neurite length measured at T=12 and T=0. Values plotted are the meanUS.E.M. for n=3. *P6 0.02 vs. control;
**P6 0.002 vs. control; ‡P6 0.01 vs. RA and DHEA alone. Bar= 100 Wm.
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analysis program, as described in Section 2. Quanti¢cation of
movements discriminates directional movements (evident in
control cells) from distances covered around the same spot
(detectable in treated cells). As shown in Fig. 1, both RA
and DHEA reduce cellular movements, which in di¡erentiat-
ing cells become stationary if compared with the random
movements of untreated cells.
3.3. RA and DHEA synergistically promote cellular
di¡erentiation
The comparison of the neurite elongation in treated and
untreated cells shown in Fig. 2A and quanti¢ed in Fig. 2B
con¢rms the di¡erentiating e¡ect of RA shown for other neu-
ronal cell lines and reveal a synergy of action between RA and
DHEA in promoting neurite extension, already evident at day
3 of treatment (Fig. 2A) and even more at day 9 (Fig. 3). In
fact the co-incubation with the two drugs emphasizes the for-
mation of a marked network of neurites. Also, when exam-
ined for 12 h, neurite elongation is enhanced by combined
treatment with RA and DHEA, as calculated in Fig. 2C.
In agreement with these data, the synergy of RA and
DHEA in promoting neuronal-like di¡erentiation is con-
¢rmed by the expression of the neuronal di¡erentiation
marker GAP-43, which is enhanced by the simultaneous treat-
ment with the two agents, as proved by immuno£uorescence
experiments shown in Fig. 3.
3.4. Synergistic action of RA and DHEA on neuroblastoma
di¡erentiation does not involve alterations in RARs
expression
In order to investigate the importance of receptor-mediated
signalling promoting di¡erentiation, we evaluated the expres-
sion pattern of two RARs, the isoforms L and K, and the
expression of one of the modulators of heterodimers forma-
tion, RXR L. Moreover, we checked the presence in SK-N-BE
cells of one of the candidate receptors for DHEA metabolites,
estrogen receptor K (ER K). As shown in Fig. 4, both RAR K
and L expression is increased after exposure to RA, as known
for other cell lines, but not further enhanced by the co-incu-
bation with DHEA, which has no e¡ect on these receptors,
alone or in combination with RA. RXR L expression does not
seem to be modulated by either drug. Whatever the di¡eren-
tiating e¡ect of DHEA may be, it does not seem to be medi-
ated by the ER K receptor, because the latter was not detect-
able on SK-N-BE cells, both in presence or absence of
DHEA.
3.5. Modulation of metalloproteinases during di¡erentiation
One of the mechanisms leading to invasion of the extracel-
lular matrix and eventually to cell migration is the enhanced
Fig. 3. Increased expression of GAP-43, detected by immuno£uores-
cence after 9 days of treatments. Cells were seeded onto coverslips,
treated for 9 days with the two agents alone or in combination, and
subsequently stained with anti-GAP-43 antibody. Images were taken
from a representative experiment out of three. Bar= 100 Wm.
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Fig. 4. Western blot analysis of RARs in SK-N-BE cells treated for 9 days with RA and DHEA, alone or in combination. Total cell lysates
were immunoblotted and incubated with antibodies against the receptors as marked on the left. A positive control (+: MCF-7 cell extract) was
included in the blot incubated with the antibody against ER alpha, in order to check the antibody e⁄ciency and con¢rm the negative results
given by SK-N-BE cell extracts.
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production of membrane-bound or secreted metalloprotei-
nases. We therefore analyzed the activity of metalloprotei-
nases produced by untreated cells or after exposure to RA
and DHEA. Zymogram studies shown in Fig. 5 reveal the
presence of two main metalloproteinases, which due to their
molecular weight can be identi¢ed as MMP-2 and MMP-9.
MMP-2 is detectable both in total cell lysates and conditioned
media already after a short incubation (Fig. 5A), and its ac-
tivity is more evident after a prolonged analysis (Fig. 5B).
Only cell-bound MMP-2 exhibits an increase after incubation
with RA and RA+DHEA. MMP-9 activity is detectable only
after prolonged incubation, suggesting a limited production in
SK-N-BE cells, and only in the extracellular medium, indicat-
ing that it is totally secreted. Interestingly, MMP-2 is up-regu-
lated during di¡erentiation promoted by RA and not by
DHEA, whereas secretion of MMP-9 is enhanced by DHEA
and not by RA.
4. Discussion
Di¡erentiation is a process which is in many degrees lost in
tumoral cells. All-trans RA is particularly e¡ective in inducing
the activation of an endogenous di¡erentiation program, how-
ever its therapeutic potential is hampered by retinoid resis-
tance associated with many di¡erent types of cancer. Little
is known of the complex intracellular mechanisms balancing
proliferation and di¡erentiation state, and a shift toward the
latter could be achieved by combined treatments.
With this in mind, we set out to investigate patterns of
enhancement of RA e¡ects. We provide here evidence sup-
porting the potentiating e¡ect of a neurosteroid on RA-in-
duced neuroblastoma cell di¡erentiation. In our study, upon
treatment with RA and DHEA, SK-N-BE cells slow down
their proliferation rate and develop a di¡erentiated mor-
phology, detectable as neurite sprouting and enhanced ex-
pression of a di¡erentiation marker, the protein GAP-43. In
agreement with a di¡erentiating process taking place, in the
same conditions cellular motility decreases and changes its
features, becoming more stationary. Anti-proliferative and
di¡erentiating properties of RA and DHEA were already
known [27,28], both on neuroblastoma and other cell lines,
but we have shown here a reciprocal potentiation of their
e¡ect.
Even when grown in vitro, neuroblastoma cells are able to
secrete matrix components [29,30], and a boosted ECM re-
modelling triggered by proteinases could rush the di¡erentia-
tion process. Indeed, in our experimental model increased
neurite elongation goes along with a di¡erentially modulated
expression of proteinases. In fact RA treatment enhances the
expression of the metalloproteinase MMP-2, whereas DHEA
exerts its e¡ects increasing the activity of the metalloprotei-
nase MMP-9.
Investigating the molecular mechanisms involved in RA
and DHEA synergy, we have found that apparently a di¡er-
ential expression of receptors is not involved. In fact, the
RARs most commonly studied in di¡erentiating protocols,
RAR K and L, and RXR L, in our experiments give a li-
gand-induced response (RARs) or a basal expression (RXR)
which is not further enhanced by the co-treatment with
DHEA. It is not clear whether DHEA acts as such or as
precursor of estrogens. Our cellular system does not express
the ER K, a well-known player of di¡erentiation events, there-
fore we can rule out its involvement. Up to now no receptor
has ever been isolated for DHEA itself, apart from a reported
putative plasma membrane DHEA receptor coupled to
G-proteins [31]. Recent experimental evidence indicate that
some steroid hormones, besides their well-documented ge-
nomic actions, could produce non-genomic rapid e¡ects,
such as regulation of calcium transients [15,32]. Interestingly,
a di¡erential secretion of MMP-9 upon calcium entry has
been reported in keratinocytes and murine carcinoma cells,
due to a calcium-responsive element in the promoter region
[33], whereas MMP-2 activity seems to be una¡ected by cal-
cium signalling [34]. It is therefore reasonable to hypothesize a
calcium-dependent transcriptional induction of MMP-9 trig-
gered by DHEA.
Taken together, our data highlight the role of DHEA as
enhancer of RA di¡erentiating e¡ect on neuroblastoma cells.
Such a synergy might be the result of a concerted regulation
at the genomic level (MMPs expression) not involving classi-
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Fig. 5. E¡ect of RA and DHEA on metalloproteinases activity. Treatment of SK-N-BE cells for 9 days with the two drugs was followed by zy-
mographic analysis of secreted metalloproteinases from conditioned media or cell-associated metalloproteinase activity from cell lysates. Total
lysates or conditioned media were electrophoresed and gelatin digestion was carried out for 16 h (A) or 5 days (B), as described in Section 2.
Lysis zones corresponding to MMP-9 and MMP-2 are indicated on the right.
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cal retinoid receptors but arising from a local modulation of
intracellular calcium levels.
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